Reversing a longstanding policy, the US government said on Friday that human and other genes should not be eligible for patents. The new position could have a huge impact on medicine and on the biotechnology industry.
The new position was declared in a friend-of-the-court brief filed by the US Department of Justice late on Friday in a case involving two human genes linked to breast and ovarian cancer.
“We acknowledge that this conclusion is contrary to the longstanding practice of the Patent and Trademark Office, as well as the practice of the National Institutes of Health and other government agencies that have in the past sought and obtained patents for isolated genomic DNA,” the brief said.
It is not clear if the position in the legal brief, which appears to have been the result of discussions among various government agencies, will be put into effect by the Patent Office.
If it were, it is likely to draw protests from some biotechnology companies that say such patents are vital to the development of diagnostic tests, drugs and the emerging field of personalized medicine, in which drugs are tailored for individual patients based on their genes.
“It’s major when the United States, in a filing, reverses decades of policies on an issue that everyone has been focused on for so long,” said Edward Reines, a patent attorney who represents biotechnology companies.
The issue of gene patents has long been a controversial and emotional one. Opponents say that genes are products of nature, not inventions, and should be the common heritage of mankind. They say that locking up basic genetic information in patents actually impedes medical progress.
Proponents say genes isolated from the body are chemicals that are different from those found in the body and therefore are eligible for patents.
The Patent and Trademark Office has sided with the proponents and has issued thousands of patents on the genes of various organisms, including on an estimated 20 percent of human genes.
However, in its brief, the government said it now believed that the mere isolation of a gene, without further alteration or -manipulation, did not change its nature.
“The chemical structure of native human genes is a product of nature, and it is no less a product of nature when that structure is ‘isolated’ from its natural environment than are cotton fibers that have been separated from cotton seeds or coal that has been extracted from the earth,” the brief said.
However, the government suggested such a change would have limited impact on the biotechnology industry because man-made manipulations of DNA, like methods to create genetically modified crops or gene therapies, could still be patented.
James Evans, a professor of genetics and medicine at the University of North Carolina who headed a government advisory task force on gene patents, called the government’s brief “a bit of a landmark, kind of a line in the sand.”
He said that although gene -patents had been issued for decades, the patentability of genes had never been examined in court.
That changed when the American Civil Liberties Union and the Public Patent Foundation organized various individuals, medical researchers and societies to file a lawsuit challenging patents held by Myriad Genetics and the University of Utah Research Foundation. The patents cover two genes, BRCA1 and BRCA2, and the over US$3,000 analysis Myriad performs on the genes to see if women carry mutations that predispose them to breast and ovarian cancers.
In a surprise ruling in March, Judge Robert Sweet of the US District Court in Manhattan ruled the patents invalid. He said genes were important for the information they convey, and in that sense, an isolated gene was not really different from a gene in the body. The -government said that ruling prompted it to re-evaluate its policy.
Myriad and the University of Utah have appealed.
Saying that the questions in the case were “of great importance to the national economy, to medical science and to the public health,” the Justice Department filed an amicus brief that sided with neither party. While the government took the plaintiffs’ side on the issue of isolated DNA, it sided with Myriad on patentability of manipulated DNA.
Myriad and the plaintiffs did not comment on the government’s brief by deadline for this article.
Reines, who is with the firm of Weil Gotshal & Manges and is not involved in the main part of the Myriad case, said he thought the Patent Office opposed the new position, but was overruled by other agencies. A hint is that no lawyer from the Patent Office was listed on the brief.
BLOODSHED: North Koreans take extreme measures to avoid being taken prisoner and sometimes execute their own forces, Ukrainian President Volodymyr Zelenskiy said Ukrainian President Volodymyr Zelenskiy on Saturday said that Russian and North Korean forces sustained heavy losses in fighting in Russia’s southern Kursk region. Ukrainian and Western assessments say that about 11,000 North Korean troops are deployed in the Kursk region, where Ukrainian forces occupy swathes of territory after staging a mass cross-border incursion in August last year. In his nightly video address, Zelenskiy quoted a report from Ukrainian Commander-in-Chief Oleksandr Syrskyi as saying that the battles had taken place near the village of Makhnovka, not far from the Ukrainian border. “In battles yesterday and today near just one village, Makhnovka,
Russia and Ukraine have exchanged prisoners of war in the latest such swap that saw the release of hundreds of captives and was brokered with the help of the United Arab Emirates (UAE), officials said on Monday. Ukrainian President Volodymyr Zelenskiy said that 189 Ukrainian prisoners, including military personnel, border guards and national guards — along with two civilians — were freed. He thanked the UAE for helping negotiate the exchange. The Russian Ministry of Defense said that 150 Russian troops were freed from captivity as part of the exchange in which each side released 150 people. The reason for the discrepancy in numbers
The foreign ministers of Germany, France and Poland on Tuesday expressed concern about “the political crisis” in Georgia, two days after Mikheil Kavelashvili was formally inaugurated as president of the South Caucasus nation, cementing the ruling party’s grip in what the opposition calls a blow to the country’s EU aspirations and a victory for former imperial ruler Russia. “We strongly condemn last week’s violence against peaceful protesters, media and opposition leaders, and recall Georgian authorities’ responsibility to respect human rights and protect fundamental freedoms, including the freedom to assembly and media freedom,” the three ministers wrote in a joint statement. In reaction
BARRIER BLAME: An aviation expert questioned the location of a solid wall past the end of the runway, saying that it was ‘very bad luck for this particular airplane’ A team of US investigators, including representatives from Boeing, on Tuesday examined the site of a plane crash that killed 179 people in South Korea, while authorities were conducting safety inspections on all Boeing 737-800 aircraft operated by the country’s airlines. All but two of the 181 people aboard the Boeing 737-800 operated by South Korean budget airline Jeju Air died in Sunday’s crash. Video showed the aircraft, without its landing gear deployed, crash-landed on its belly and overshoot a runaway at Muan International Airport before it slammed into a barrier and burst into flames. The plane was seen having engine trouble.
RSS